Cours suspendu

Autres langues Exscientia plc

Actions

EXAI

US30223G1022

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 19/11/2024			Varia. 5j.	Varia. 1 janv.
4,840 ^USD	+3,20%		-.--%	-

20/11/24	Recursion Pharmaceuticals et Exscientia achèvent le regroupement de leurs activités	MT
20/11/24	Recursion annonce des changements de direction	CI

Autres langues

21/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index
20/11/24	Exscientia : Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Form 6 K
20/11/24	Recursion Pharmaceuticals, Exscientia Complete Business Combination
20/11/24	Recursion Appoints Ben Taylor as Chief Financial Officer
20/11/24	Recursion Announces Management Changes
20/11/24	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
20/11/24	Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc.
20/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Composite Index
20/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Biotechnology Index
13/11/24	Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination Form 6 K
13/11/24	Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination
08/11/24	Exscientia : Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Form 6 K
08/11/24	Exscientia plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
06/11/24	Exscientia : FIRST AMENDMENT TO TRANSACTION AGREEMENT Form 6 K
17/10/24	Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi
16/10/24	Exscientia Expects $15 Million in Milestone Payments From Sanofi
16/10/24	Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
10/10/24	Exscientia : Proposed acquisition of the Company 1 Form 6 K
09/10/24	Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren
09/10/24	Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
01/10/24	Rallybio Corporation - Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
28/08/24	Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen
28/08/24	Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
15/08/24	Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024
15/08/24	Exscientia plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024